Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
about
Oncogenic kinase fusions: an evolving arena with innovative clinical opportunitiesPersonalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicineComprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.Systemic therapies in the treatment of non-small-cell lung cancer brain metastases.The impact of immunohistochemistry on the classification of lung tumors.Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms.Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancer.Debunking the Delusion That Precision Oncology Is an Illusion.Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma.Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo.Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.A phosphoarray platform is capable of personalizing kinase inhibitor therapy in head and neck cancers.Translational gap in ongoing clinical trials for glioma.Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment.Towards precision oncology in RET-aberrant cancers.Best Practices in Treatment Selection for Patients With Advanced NSCLC.Neuroimaging Biomarkers of mTOR Inhibition on Vascular and Metabolic Functions in Aging Brain and Alzheimer's Disease
P2860
Q26768158-5852DC4E-9579-42F9-9EA8-5593DFAE04F7Q36562114-0D575435-3AAA-49F0-90E6-2457B27B26CEQ37009001-52E965DB-9CC0-4D67-A7B4-DBD8C33EA234Q38738053-0BA4C1F7-EB13-4F26-88A2-CC5B79C850B0Q38822314-FC710CFA-93ED-4CBC-BAAA-F389B8D9040CQ40483555-938FF45E-E3BD-4EBE-86C0-B72551A55705Q45065453-5BC681AB-4C1E-495B-BF8F-997DB34BEE54Q46512789-B2B63C49-3E0A-47B7-A7BD-81AC0CEDAC1DQ46539715-06BDF48B-BD3F-43F9-95B0-614FF158CF4AQ46556584-E570402E-90A8-414F-9C57-3A605011DB12Q47123875-40804DD5-F048-4D44-B307-420363330B74Q47601932-DF771D5A-6057-4ED0-B41B-8D8688BA8605Q47804358-6A9F63B7-4ABA-4C81-8AA9-1477D2EB76B4Q48002716-C8E78570-D33B-470B-B325-DF5AAD1D1862Q52318443-ED6FBF31-3793-4BD4-802C-F3737E25B589Q52781139-7929D2E9-12A2-40C9-B075-E55F67BC3B2FQ52814108-FC317C11-91FD-40AE-9F29-FFC2D46CD597Q57174537-69671611-2A41-43F1-B28D-4643F5CB29EC
P2860
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 April 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Systemic and CNS activity of t ...... cancer with brain metastases.
@en
Systemic and CNS activity of t ...... cancer with brain metastases.
@nl
type
label
Systemic and CNS activity of t ...... cancer with brain metastases.
@en
Systemic and CNS activity of t ...... cancer with brain metastases.
@nl
prefLabel
Systemic and CNS activity of t ...... cancer with brain metastases.
@en
Systemic and CNS activity of t ...... cancer with brain metastases.
@nl
P2093
P2860
P1433
P1476
Systemic and CNS activity of t ...... cancer with brain metastases.
@en
P2093
Caitlin McMahon
Ishwaria Mohan Subbiah
Jenny Berry
Michael Roxas
Nandita Guha-Thakurta
Shobha Pai
Siraj M Ali
Tina Cascone
Vincent Miller
Vivek Subbiah
P2860
P356
10.1016/J.LUNGCAN.2015.04.004
P577
2015-04-22T00:00:00Z